These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34618378)

  • 1. Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and/or mirabegron for refractory daytime urinary incontinence: A retrospective cohort study.
    Pedersen N; Breinbjerg A; Thorsteinsson K; Hagstrøm S; Rittig S; Kamperis K
    Neurourol Urodyn; 2022 Jan; 41(1):275-280. PubMed ID: 34618378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of transcutaneous electrical neural stimulation therapy in patients with urinary incontinence resistant to initial medical treatment or biofeedback.
    Tugtepe H; Thomas DT; Ergun R; Kalyoncu A; Kaynak A; Kastarli C; Dagli TE
    J Pediatr Urol; 2015 Jun; 11(3):137.e1-5. PubMed ID: 25824876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of outcome in children and adolescents with overactive bladder treated with parasacral transcutaneous electrical nerve stimulation.
    Hoffmann A; Sampaio C; Nascimento AA; Veiga ML; Barroso U
    J Pediatr Urol; 2018 Feb; 14(1):54.e1-54.e6. PubMed ID: 28974365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison and characteristics of children successfully treated for daytime urinary incontinence.
    Jessen AS; Hagstroem S; Borch L
    J Pediatr Urol; 2022 Feb; 18(1):24.e1-24.e9. PubMed ID: 34930690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of transcutaneous electrical nerve stimulation in children with overactive bladder refractory to pharmacotherapy.
    Malm-Buatsi E; Nepple KG; Boyt MA; Austin JC; Cooper CS
    Urology; 2007 Nov; 70(5):980-3. PubMed ID: 17919697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parasacral transcutaneous electrical nerve stimulation for overactive bladder in constipated children: The role of constipation.
    Veiga ML; Costa EV; Portella I; Nacif A; Martinelli Braga AA; Barroso U
    J Pediatr Urol; 2016 Dec; 12(6):396.e1-396.e6. PubMed ID: 27426685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous electrical nerve stimulation for refractory daytime urinary urge incontinence.
    Hagstroem S; Mahler B; Madsen B; Djurhuus JC; Rittig S
    J Urol; 2009 Oct; 182(4 Suppl):2072-8. PubMed ID: 19695629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No immediate effect on urodynamic parameters during transcutaneous electrical nerve stimulation (TENS) in children with overactive bladder and daytime incontinence-A randomized, double-blind, placebo-controlled study.
    Borch L; Rittig S; Kamperis K; Mahler B; Djurhuus JC; Hagstroem S
    Neurourol Urodyn; 2017 Sep; 36(7):1788-1795. PubMed ID: 27868230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial.
    Sillén U; Arwidsson C; Doroszkiewicz M; Antonsson H; Jansson I; Stålklint M; Abrahamsson K; Sjöström S
    J Pediatr Urol; 2014 Dec; 10(6):1100-5. PubMed ID: 24881806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
    Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
    J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcutaneous sacral electrical stimulation versus oxibutynin for the treatment of overactive bladder in children.
    Casal-Beloy I; García-Novoa MA; García González M; Acea Nebril B; Somoza Argibay I
    J Pediatr Urol; 2021 Oct; 17(5):644.e1-644.e10. PubMed ID: 34176749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sacral transcutaneous electrical nerve stimulation in patients with overactive bladder refractory to anticholinergic treatment: a prospective multi-center study.
    Coronas Soucheiron M; Casal Beloy I; Villalón Ferrero FN; Martín Solé O; Capdevila Vilaró B; González Temprano N; Larreina De la Fuente L; García González M; Carbonell Pradas M; Pérez Bertólez S; Tarrado Castellarnau X; García Aparicio L; Somoza Argibay I
    Cir Pediatr; 2023 Oct; 36(4):180-185. PubMed ID: 37818900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parasacral transcutaneous electrical neural stimulation (PTENS) once a week for the treatment of overactive bladder in children: A randomized controlled trial.
    de Paula LIDS; de Oliveira LF; Cruz BP; de Oliveira DM; Miranda LM; de Moraes Ribeiro M; Duque RO; de Figueiredo AA; de Bessa J; Netto JMB
    J Pediatr Urol; 2017 Jun; 13(3):263.e1-263.e6. PubMed ID: 28089606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vibegron shows high efficacy in pediatric patients with refractory daytime urinary incontinence.
    Hyuga T; Tanabe K; Kubo T; Nakamura S; Nakai H; Moriya K
    Neurourol Urodyn; 2023 Apr; 42(4):794-798. PubMed ID: 36840745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
    Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
    Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.
    Shin JH; Choo MS
    Low Urin Tract Symptoms; 2019 May; 11(3):151-157. PubMed ID: 30623583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.